Larry Norton

Q: What Schools Are Affiliated With Larry Norton

Larry Norton is affiliated with the following schools: Harvard University, University of Vermont, Institute of Cancer Research, MD Anderson Cancer Center, California Institute of Technology, University of Michigan, University of Southern California, Baylor College of Medicine, Cornell University, University of Toronto, University of California, San Francisco, University of Turin, Massachusetts General Hospital, New York University, Duke University, Yale University, Hebrew University of Jerusalem, Stanford University

Larry Norton's AcademicInfluence.com Rankings

Larry Norton

Computer Science

#3633

World Rank

#3817

Historical Rank

Machine Learning

#489

World Rank

#495

Historical Rank

Artificial Intelligence

#698

World Rank

#709

Historical Rank

Database

#960

World Rank

#1008

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Larry Norton's Degrees

Masters Artificial Intelligence Stanford University

Similar Degrees You Can Earn

Best Online Master's in Artificial Intelligence 2025

Why Is Larry Norton Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Larry Norton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (2001) (10106)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. (1999) (1638)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. (2003) (1462)
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. (1996) (1402)
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. (1994) (1400)
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007) (1333)
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. (2003) (1284)
Tumor Self-Seeding by Circulating Cancer Cells (2009) (1183)
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer (2003) (1091)
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. (1998) (1085)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. (2005) (1044)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. (2002) (1035)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. (2007) (991)
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. (2004) (958)
Exogenous Expression of N-Cadherin in Breast Cancer Cells Induces Cell Migration, Invasion, and Metastasis (2000) (939)
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) (893)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. (2004) (880)
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018) (820)
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. (1996) (760)
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. (2000) (759)
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial (2000) (746)
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. (1994) (692)
A Gompertzian model of human breast cancer growth. (1988) (687)
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) (661)
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. (2009) (647)
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial (2004) (647)
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. (1998) (625)
Tumor entrained neutrophils inhibit seeding in the premetastatic lung. (2011) (616)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. (2001) (577)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. (2008) (571)
Symptom prevalence, characteristics and distress in a cancer population (1994) (571)
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. (1998) (566)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† (2014) (566)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) (529)
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. (2008) (527)
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. (2003) (472)
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss (2016) (450)
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. (1993) (444)
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. (2002) (435)
HER2 and response to paclitaxel in node-positive breast cancer. (2007) (433)
Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer (2017) (424)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. (2006) (418)
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab (2011) (414)
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2017) (405)
Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial (1998) (405)
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. (1998) (397)
Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. (2005) (386)
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% (1996) (383)
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. (2013) (361)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer (2006) (361)
Long‐term adjustment of survivors of early‐stage breast carcinoma, 20 years after adjuvant chemotherapy (2003) (348)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. (2018) (348)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. (2007) (343)
Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer (2002) (339)
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. (1982) (337)
Is cancer a disease of self-seeding? (2006) (335)
BRCA-associated breast cancer in young women. (1998) (323)
Novel patterns of genome rearrangement and their association with survival in breast cancer. (2006) (322)
Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2 (2000) (317)
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer (1996) (315)
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment (2003) (315)
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families (1996) (313)
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. (1999) (309)
1st International consensus guidelines for advanced breast cancer (ABC 1). (2012) (308)
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33 (2008) (304)
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. (1993) (284)
Clinical implications of cancer self-seeding (2011) (271)
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer (2010) (269)
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer (2001) (266)
The Epidermal Growth Factor Receptor Modulates the Interaction of E-cadherin with the Actin Cytoskeleton* (1998) (266)
Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis (2011) (260)
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. (1997) (254)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation (2002) (235)
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2014) (229)
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. (2004) (229)
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. (2012) (227)
Adjuvant chemotherapy in older women with early-stage breast cancer. (2009) (220)
MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. (2011) (219)
Cancer therapy shapes the fitness landscape of clonal hematopoiesis (2020) (218)
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. (2007) (215)
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. (2000) (213)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). (2016) (208)
Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial (2001) (202)
TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. (2013) (202)
ESO-ESMO 2 nd international consensus guidelines for advanced breast cancer ( ABC 2 ) (2014) (201)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial (2001) (190)
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. (2003) (189)
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155- (2001) (185)
Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane (2005) (182)
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. (2000) (182)
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. (2008) (179)
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. (1997) (179)
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands (2014) (178)
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. (1999) (172)
Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. (2005) (167)
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer (2012) (166)
SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers (2008) (165)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer (2017) (156)
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes (2017) (156)
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. (1996) (156)
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. (1996) (152)
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. (1995) (147)
Metastatic breast cancer. Length and quality of life. (1991) (147)
Evolving concepts in the systemic drug therapy of breast cancer. (1997) (145)
Germline BRCA1 185delAG mutations in Jewish women with breast cancer (1996) (142)
Expression of WT1, CA 125, and GCDFP-15 as Useful Markers in the Differential Diagnosis of Primary Ovarian Carcinomas Versus Metastatic Breast Cancer to the Ovary (2005) (140)
Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib (2011) (137)
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. (2007) (135)
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling (2016) (135)
Focus on breast cancer. (2002) (132)
Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2 (2005) (130)
Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. (2005) (129)
Genomic landscape of adenoid cystic carcinoma of the breast (2015) (128)
Factors influencing treatment patterns of breast cancer patients age 75 and older. (2003) (128)
A pilot study of Interpersonal Psychotherapy by telephone with cancer patients and their partners (2000) (125)
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth (2009) (124)
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations (2014) (123)
Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. (2011) (121)
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. (1999) (119)
The Genomic Landscape of Male Breast Cancers (2016) (118)
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. (2000) (117)
American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. (2017) (117)
A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer (2008) (115)
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. (2005) (114)
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer (2018) (112)
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. (2001) (111)
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification (2015) (110)
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas (2017) (109)
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy (2016) (109)
Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis (1995) (108)
N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties (2014) (108)
A phase I-II study of intensive-dose adriamycin for advanced breast cancer. (1987) (108)
The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. (2014) (106)
Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. (2005) (104)
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. (2008) (104)
Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples (2017) (103)
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient’s perspective (2006) (98)
Current management of lesions associated with an increased risk of breast cancer (2015) (97)
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. (2005) (97)
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (97)
Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis (2007) (97)
BRCA-associated breast cancer: absence of a characteristic immunophenotype. (1998) (96)
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. (1996) (96)
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial (2006) (92)
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. (2006) (91)
Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression (2016) (90)
Intracystic Papillary Carcinoma of the Breast: An In Situ or Invasive Tumor? Results of Immunohistochemical Analysis and Clinical Follow-up (2011) (90)
Living with Metastatic Breast Cancer: A Qualitative Analysis of Physical, Psychological, and Social Sequelae (2013) (89)
Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. (1989) (89)
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer (2005) (89)
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (2016) (88)
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours (2006) (85)
Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy. (1995) (84)
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity (1994) (83)
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. (2012) (83)
Modeling the development of metastases from primary and locally recurrent tumors: comparison with a clinical data base for prostatic cancer. (1993) (82)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. (2002) (81)
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors (2020) (81)
Metastatic hypernephroma to the head and neck. (1987) (81)
Adjuvant trastuzumab with chemotherapy is effective in women with small, node‐negative, HER2‐positive breast cancer (2011) (80)
Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21 (2007) (80)
Association of angiogenesis in lymph node metastases with outcome of breast cancer. (2000) (79)
The AURORA initiative for metastatic breast cancer (2014) (79)
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. (2005) (78)
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases (2017) (78)
Genetic Alterations of Triple Negative Breast Cancer By Targeted Next Generation Sequencing And Correlation With Tumor Morphology (2016) (78)
Immunophenotype of intraductal carcinoma. (1996) (78)
Abstract P5-14-04: Effects of dose-dense chemotherapy on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials (2017) (76)
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). (2014) (76)
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. (2001) (76)
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (75)
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. (2003) (75)
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. (2016) (75)
Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study (2015) (75)
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. (2015) (75)
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. (2002) (75)
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. (2018) (74)
Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? (1995) (74)
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) (2016) (73)
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). (2014) (73)
An experimental analysis of classically conditioned nausea during cancer chemotherapy. (1992) (73)
Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. (2013) (73)
Growth Curve Analysis (2003) (71)
Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival (2014) (71)
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. (1991) (69)
Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients (2006) (68)
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. (2008) (68)
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. (2008) (67)
Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. (1980) (66)
Optimization of Conditions for Ex Vivo Expansion of CD34' Cells From Patients With Stage IV Breast Cancer (1994) (65)
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. (1977) (65)
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. (2008) (63)
Sleep problems in breast cancer survivors 1–10 years posttreatment (2017) (63)
Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments (2004) (62)
The Genomic Landscape of Mucinous Breast Cancer. (2019) (60)
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. (1996) (59)
Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. (2006) (58)
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene (2018) (58)
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. (1999) (58)
Randomised trial of expressive writing for distressed metastatic breast cancer patients (2012) (58)
Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. (1983) (57)
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2014) (57)
A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). (2016) (57)
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. (2005) (56)
Potential innovations in scheduling of cancer chemotherapy. (1991) (54)
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. (1997) (54)
Experimental and clinical activity of mitomycin C and cis-diamminedichloroplatinum in malignant mesothelioma. (1984) (52)
The genetic landscape of breast carcinomas with neuroendocrine differentiation (2017) (52)
Role of anthracyclines in the treatment of early breast cancer. (2009) (51)
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. (2016) (51)
Theoretical concepts and the emerging role of taxanes in adjuvant therapy. (2001) (50)
Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast (2017) (50)
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. (2010) (50)
Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high‐dose chemotherapy plus granulocyte‐macrophage colony‐stimulating factor a randomized trial (1993) (49)
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis‐generating study (2015) (49)
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. (2011) (48)
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors (2016) (48)
Formation of food aversions in cancer patients receiving repeated infusions of chemotherapy. (1993) (48)
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy (2005) (48)
Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. (1998) (48)
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2018) (47)
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. (2010) (46)
Genetic Analysis of Microglandular Adenosis and Acinic Cell Carcinomas of the Breast Provides Evidence for the Existence of a Low-grade Triple-Negative Breast Neoplasia Family (2016) (46)
Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. (2011) (46)
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy (2004) (46)
Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. (1993) (46)
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (2012) (46)
Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer. (1999) (46)
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. (1999) (45)
The MORE Trial: Multiple Outcomes for Raloxifene Evaluation (2001) (45)
Metastatic breast carcinomas display genomic and transcriptomic heterogeneity (2015) (45)
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. (2019) (42)
Cancer stem cells, self-seeding, and decremented exponential growth: theoretical and clinical implications. (2008) (42)
Chemotherapy of metastatic Merkel cell cancer. (1991) (41)
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. (1993) (41)
Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer (2005) (40)
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. (2001) (40)
p21CIP1 mediates reciprocal switching between proliferation and invasion during metastasis (2013) (40)
Dose-dense adjuvant chemotherapy for primary breast cancer (2005) (40)
Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment (1997) (39)
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (2022) (39)
Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis. (2014) (39)
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. (2016) (39)
Self-seeding in cancer. (2012) (38)
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation (2012) (38)
Factors Associated with Influenza Vaccination Decisions among Patients with Mental Illness (2013) (38)
DNA Mismatch Repair Deficiency in Breast Carcinoma: A Pilot Study of Triple-negative and Non–Triple-negative Tumors (2012) (37)
Kinetic concepts in the systemic drug therapy of breast cancer. (1999) (37)
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. (2019) (36)
Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping (2008) (36)
Conditioned emotional distress in women receiving chemotherapy for breast cancer. (1995) (36)
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. (1999) (35)
Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). (2004) (35)
Use of ultrasound to guide radiation boost planning following lumpectomy for carcinoma of the breast. (1993) (35)
Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (34)
Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites (2015) (34)
Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer (2004) (33)
Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907 (2008) (32)
Clonal hematopoiesis is associated with risk of severe Covid-19 (2020) (32)
Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials (2018) (32)
Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer. (1994) (32)
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) (2011) (32)
Paradigms for Precision Medicine in Epichaperome Cancer Therapy. (2019) (31)
Cytokeratin‐positive cells in sentinel lymph nodes in breast cancer are not random events (2004) (31)
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer (2008) (31)
Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer (2005) (31)
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. (2010) (31)
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study (2016) (31)
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. (2002) (30)
Metastatic breast carcinomas display genomic and transcriptomic heterogeneity (2015) (30)
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy (2019) (30)
Sources of anticipatory emotional distress in women receiving chemotherapy for breast cancer. (1995) (30)
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer (2017) (29)
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. (2008) (29)
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases (2019) (29)
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. (1996) (29)
A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer (2011) (28)
Migration of transfused granulocytes in leukopenic dogs. (1977) (28)
Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor (2016) (27)
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. (2013) (27)
Immunohistochemical Detection of Cathepsin D in T2N0M0 Breast Carcinoma (1994) (27)
A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization (2019) (27)
Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). (2006) (27)
The 6q22.33 Locus and Breast Cancer Susceptibility (2009) (27)
The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery. (1996) (27)
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. (2002) (26)
Existential concerns in late stage cancer. (2002) (26)
Salvage chemotherapy of breast cancer. (1994) (26)
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806 (2006) (25)
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. (2009) (25)
Clonal hematopoiesis is associated with risk of severe Covid-19 (2021) (25)
Adjuvant drug therapy for operable breast cancer. (1996) (25)
Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion Vaccine (2007) (25)
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis (2017) (24)
Association between Bone Mineral Density and Incidence of Breast Cancer (2013) (24)
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer (2018) (24)
Conceptual basis for advances in the systemic drug therapy of breast cancer. (1997) (24)
A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non‐Hodgkin's lymphomas cancer and leukemia group B study 7851 (1990) (24)
Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors. (2015) (23)
Somatic mutations in leukocytes infiltrating primary breast cancers (2015) (23)
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. (2003) (23)
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. (2017) (23)
Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. (1995) (22)
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy. (1995) (22)
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer (2001) (22)
Oncologic therapy shapes the fitness landscape of clonal hematopoiesis (2019) (22)
Rare de novo germline copy-number variation in testicular cancer. (2012) (21)
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer (2011) (21)
Microdissection and Molecular Genetic Analysis of HER2/neu in Breast Carcinoma (1995) (21)
Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients. (1994) (21)
Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia (2016) (20)
Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer. (1997) (20)
A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). (2013) (20)
Changing indications for surgery in patients with stage IV breast cancer (2008) (20)
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma (2020) (19)
TNF is a key cytokine mediating neutrophil cytotoxic activity in breast cancer patients (2016) (19)
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma (2021) (19)
Localization of breast cancer susceptibility loci by genome‐wide SNP linkage disequilibrium mapping (2006) (19)
Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: a CALGB study. (1990) (18)
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. (2010) (18)
Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. (2017) (18)
Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial. (1994) (18)
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. (2015) (18)
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. (1999) (18)
Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer. (2009) (18)
Timing of radiotherapy in the treatment of early-stage breast cancer. (1993) (17)
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer (2011) (17)
Long‐term cardiac safety and outcomes of dose‐dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer (2013) (17)
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. (2008) (16)
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow‐up (2017) (16)
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. (1991) (16)
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. (2020) (16)
Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. (2020) (16)
Kinetic Concepts in the Treatment of Breast Cancer (1993) (15)
Change in Cycle 1 to Cycle 2 Haematological Counts Predicts Toxicity in Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy (2005) (15)
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group (2011) (15)
The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas (2020) (15)
Translating Mathematical Modeling of Tumor Growth Patterns into Novel Therapeutic Approaches for Breast Cancer (2012) (15)
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) (2009) (15)
Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. (1997) (15)
Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact (2017) (15)
Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans. (1985) (15)
Saving Women's Lives: Strategies for Improving Breast Cancer Detection and Diagnosis: A Breast Cancer Research Foundation and Institute of Medicine Symposium (2005) (15)
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with prosorba columns for treating metastatic breast cancer (1995) (14)
Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM) (2017) (14)
Cancer log-kill revisited. (2014) (14)
Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo. (1978) (14)
The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers (2019) (14)
Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. (2019) (14)
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. (2004) (14)
High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 co-amplification is uncommon in human breast cancer. (2009) (13)
Accuracy of Magnetic Resonance Imaging–Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy (2021) (13)
Phase II trial of carboplatin and etoposide in metastatic breast cancer (1993) (13)
Screening chest imaging studies are not effective in the follow-up of breast cancer patients. (2003) (13)
High-dose chemotherapy for breast cancer: "how do you know?". (2001) (13)
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma (2009) (13)
Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG (2005) (13)
Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). (2006) (13)
A randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851. (1987) (13)
A Rare Case of S310F Somatic ERBB2 Mutation in a HER2‐Nonamplified Breast Cancer (2017) (13)
The 21-Gene Recurrence Score in Male Breast Cancer (2018) (13)
Advances in managing breast cancer: a clinical update (2014) (12)
Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer (2007) (12)
Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. (1999) (12)
Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer (2013) (12)
Hyperglycemic Complications Associated with Adjuvant Chemotherapy of Breast Cancer A Cancer and Leukemia Group B (CALGB) Study (1986) (12)
The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features (2021) (12)
Fractional SIR Epidemiological Models (2020) (12)
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. (2008) (12)
An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis. (2018) (12)
The IL-6 / JAK / Stat 3 Feed-Forward Loop Drives Tumorigenesis and Metastasis 1 , 2 (2013) (11)
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. (1993) (11)
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. (2016) (11)
Multi-center prospective analysis of risk-reducing salpingo-oophorectomy to prevent BRCA-associated breast and ovarian cancer. (2006) (11)
Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs. (1978) (11)
Phase II study of semisynthetic paclitaxel in metastatic breast cancer. (1997) (11)
Fractional SIR epidemiological models (2020) (11)
PD09-08: Combined Inhibition of mTORC1 with Temsirolimus and HER2 with Neratinib: A Phase I/II Study in Patients with Metastatic HER2−Amplified or Triple-Negative Breast Cancer. (2011) (11)
Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041) (2004) (11)
Kinetic concepts in the treatment of breast cancer. (1993) (11)
Redox signaling by glutathione peroxidase 2 links vascular modulation to metabolic plasticity of breast cancer (2022) (10)
Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. (1995) (10)
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel. (1998) (10)
Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171. (1985) (10)
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. (2008) (10)
Dose-dense chemotherapy for breast cancer: what does the future hold? (2010) (10)
Correspondence re: Larry Norton, A Gompertzian Model of Human Breast Cancer Growth. Cancer Res., 48: 7067–7071, 1988—Reply (1989) (10)
A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study (2008) (9)
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer (2020) (9)
Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers. (2010) (9)
Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients (2015) (9)
An immunotherapeutic approach to treatment of breast cancer: focus on trastuzumab plus paclitaxel (2000) (9)
Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up (2018) (9)
Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary? (2018) (9)
The Roth Project - Music and Memory: A Community Agency Initiated Individualized Music Intervention for People with Dementia (2019) (9)
Evaluating clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies. (2019) (8)
American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations (2017) (8)
Decreased gastrointestinal toxicity associated with a novel capecitabine schedule (7 days on and 7 days off): a systematic review (2016) (8)
Radiation Pneumonitis in Breast Cancer Patients Treated with Taxanes: Does Sequential Radiation Therapy Lower the Risk? (2005) (8)
Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. (2009) (8)
A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC). (2019) (8)
94 Preliminary analysis of radiotherapy data from CALGB 9082: variability of treatment fields for local/regional breast cancer and the impact of high dose chemotherapy on the ability to deliver radiation therapy (1999) (8)
Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast (2017) (8)
p21CIP1 Promotes Mammary Cancer–Initiating Cells via Activation of Wnt/TCF1/CyclinD1 Signaling (2019) (8)
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. (2010) (8)
A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. (2019) (8)
The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis. (2021) (8)
A feasibility study of an aromatase inhibitor (AI), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) (2005) (8)
Survival of premenopausal women with breast carcinoma (1998) (8)
Preoperative checkpoint inhibition (CPI) and cryoablation (Cryo) in women with early-stage breast cancer (ESBC). (2019) (7)
Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. (2016) (7)
Taxol and Recombinant Human Granulocyte Colony‐Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer (1993) (7)
Use of dose-dense chemotherapy in the management of breast cancer. (2006) (7)
Prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer. (2013) (7)
Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer (1993) (7)
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases (2022) (7)
High-dose chemotherapy of breast cancer: current status and developmental strategies. (1995) (6)
Breast cancer survivors are at an increased risk for osteoporotic fractures not explained by lower BMD: a retrospective analysis (2015) (6)
Control and the Analysis of Cancer Growth Models (2018) (6)
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer (2021) (6)
Hyperactivation of the PI3K-AKT Pathway Commonly Underlies Resistance to Trastuzumab in HER2 Amplified Breast Cancer. (2009) (6)
Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model (2007) (6)
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022) (6)
Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy (2012) (5)
High‐Intensity Chemotherapy with Hematopoietic Support in Breast Cancer a (1993) (5)
Predictive Biomarkers and Personalized Medicine Frequent Mutational Activation of the PI 3 K-AKT Pathway in Trastuzumab-Resistant Breast Cancer (2012) (5)
Anti-tumor effects of an ID antagonist with no observed acquired resistance (2021) (5)
Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer (2007) (5)
Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer. (2011) (5)
Cancer of the Breast (1989) (5)
Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin- bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety (2007) (5)
Whole‐exome analysis of metaplastic breast carcinomas with extensive osseous differentiation (2020) (5)
Negative Estrogen Receptor and HER2 Assays at Core Biopsy of Invasive Cancers Should Be Confirmed in the Surgical Specimens. (2009) (5)
Cancer stem cells, EMT, and seeding: a rose is a rose is a rose? (2011) (5)
Systemic adjuvant therapy for breast cancer (1993) (5)
Abstract P5-18-04: Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer (2012) (5)
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification (2015) (5)
Log-Kill Hypothesis (2015) (5)
Beyond Jeopardy!: Harnessing IBM's Watson to improve oncology decision making. (2013) (5)
Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts) (2015) (5)
Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA) (2008) (5)
Biology of residual breast cancer after therapy: a kinetic interpretation. (1990) (5)
A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study. (2009) (4)
Increased dose-density (DD) Is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10–11 day interval with filgrastim support, for women with early breast carcinoma (BC) (2005) (4)
[Kinetics of breast neoplasms]. (1994) (4)
Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC). (2010) (4)
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer (2019) (4)
The 6 q 22 . 33 Locus and Breast Cancer Susceptibility (2009) (4)
Abstract GS4-08: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance (2022) (4)
JAK 2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors (2016) (4)
Carboplatin and etoposide in metastatic breast cancer. (1995) (4)
Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors (2021) (4)
Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2015) (4)
Escalating de-escalation in breast cancer treatment (2022) (4)
Troponins Do Not Predict Cardiotoxicity in a Pilot Study of Adjuvant Bevacizumab (B) Plus Dose-Dense Doxorubicin/Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel (nab-P). (2009) (4)
T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). (2014) (4)
Anti-tumor effects of an Id antagonist with no acquired resistance (2020) (4)
Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network (2020) (4)
Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy (2016) (4)
Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab. (2009) (4)
A Recurrent ERCC 3 Truncating Mutation Confers Moderate Risk for Breast Cancer (2016) (4)
The scientific data audit system of the cancer and leukemia group B (CALGB) (1992) (4)
Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC) (2008) (3)
A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy (2019) (3)
Supporting data sharing (2019) (3)
Taxol plus recombinant human granulocyte colony stimulating factor as salvage chemotherapy for metastatic breast cancer (1994) (3)
Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data (2013) (3)
Capecitabine dosing is not yet optimized for breast cancer. (2010) (3)
Abstract PD4-13: Estrogen receptor-negative breast adenomyoepitheliomas are driven by co-occurring HRAS hotspot and PI3K pathway gene mutations: A genetic and functional analysis (2018) (3)
Cell-to-cell communication in cancer: workshop report (2015) (3)
Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? (2012) (3)
Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. (2019) (3)
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab (2022) (3)
Abstract P6-12-09: A Phase I-II Trial of Dasatinib (D) in Combination with Weekly (w) Paclitaxel (P) for Patients (Pts) with Metastatic Breast Carcinoma (MBC) (2010) (3)
Breast cancer advocates in clinical research: a trialist's perspective. (1998) (3)
Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) (2015) (3)
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study (2022) (3)
Breast cancer fear in girls: a major “side effect” of breast cancer in loved ones and a backlash of ubiquitous media coverage. (2009) (3)
Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. (2015) (3)
Correction: Association between Bone Mineral Density and Incidence of Breast Cancer (2013) (3)
Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). (2014) (3)
COMMITTEE ON NEW APPROACHES TO EARLY DETECTION AND DIAGNOSIS OF BREAST CANCER (2005) (3)
Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer. (1994) (3)
Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study. (2010) (3)
Abstract S6-06: The genomic landscape of male breast cancers (2015) (2)
Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: no evidence of short-term changes in left ventricular ejection fraction. (2009) (2)
Truth, Science, and the Oncologist (1997) (2)
Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases (1990) (2)
Abstract OT2-06-05: A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard peri-operative care in women with residual triple negative early stage/resectable breast cancer after standard-of-care neoadjuvant chemotherapy (2019) (2)
Phase II Evaluation of a Novel Capecitabine Schedule in Combination with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab. (2009) (2)
Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience. (2006) (2)
Abstract P4-14-24: Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling (2016) (2)
Abstract S6-06: High-depth massively parallel sequencing reveals heterogeneity between primary tumor and metastatic deposits in de novo metastatic breast cancer patients prior to exposure to systemic therapy (2013) (2)
Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840 (2005) (2)
Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer. (2009) (2)
Abstract P4-13-01: A pilot study of pre-operative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC) (2013) (2)
Correlative biomarkers in a phase II study of dasatinib (D) and weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC). (2010) (2)
Two regimens of docetaxel for metastatic breast cancer (2005) (2)
Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling (2007) (2)
Tumor self-seeding in breast cancer. (2011) (2)
Effect of adjuvant chemotherapy (CRx) on the cognitive function of older patients (pts) with breast cancer (BC): Results from a prospective study (2005) (2)
Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center. (2015) (2)
Superiority of radio-opaque clips compared to ultrasound as methods of defining lumpectomy cavity volumes for breast boost planning (1998) (2)
Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer. (2022) (2)
First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients. (2020) (2)
Immunologic studies of canine lymphosarcoma: mixed leukocyte reactivity following chemotherapy. (1978) (2)
The impact of local/regional radiotherapy (RT), and its timing, on survival following lumpectomy/mastectomy and systemic chemotherapy in patients with ≥10 positive axillary nodes: Analysis of CALGB 9082 (2004) (2)
Dose-intensity, dose-escalation, and dose-density in the adjuvant chemotherapy of primary, operable breast cancer. (2001) (2)
Feasibility of breast conserving treatment for breast cancer in women with germline BRCA mutations: A clinic-based series. (2004) (2)
Local control and the sequencing of adjuvant systemic therapy with primary radiation for patients with early breast cancer (1992) (2)
Saving Women's Lives (2005) (2)
Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC) (2008) (2)
Comparative Effectiveness Research Needs to Consider Optimal Dosing and Scheduling. (2020) (1)
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy (2022) (1)
Serum peptide profiling (SPP) by mass spectrometry (MS) to identify post-menopausal women with metastatic breast cancer (2005) (1)
Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result. (2015) (1)
Abstract P2-16-12: An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer (2013) (1)
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma (2021) (1)
Selected abstracts submitted to the Third International Symposium on Hereditary Breast and Ovarian Cancer (2009) (1)
E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting (2012) (1)
Abstract P2-14-08: Patient Perspectives on Information Communicated Regarding Effects of Treatment on Fertility (2010) (1)
Dose-dense chemotherapy with trastuzumab is an appropriate option. (2008) (1)
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab (2022) (1)
Epoetin alfa: to give or not to give. (2013) (1)
Comparison of paclitaxel regimens (2005) (1)
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. (2016) (1)
The concept of mathematically optimised dose-scheduling as applied to the adjuvant chemotherapy of primary breast cancer: theory and recent results (2008) (1)
Evaluation of indibulin, a novel tubulin targeting-agent, in combination with capecitabine, with mathematically optimized dose scheduling. (2016) (1)
Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer. (2021) (1)
A Markov chain model of a longitudinal breast cancer data set. (2014) (1)
Adjuvant systemic therapy for early breast cancer (1991) (1)
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). (2013) (1)
Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 ) (2011) (1)
Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer. (2018) (1)
Faculty Opinions recommendation of Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. (2014) (1)
1005 High resolution microarray copy number analysis (array CGH) suggests that determination of HER2 amplification by FISH (FISH+) is inaccurate in human breast cancer specimens that are HER2 2+ by immunohistochemistry (IHC2+) (2009) (1)
Targeting stressor-induced dysfunctions in protein-protein interaction networks via epichaperomes. (2022) (1)
Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) (2014) (1)
Abstract P5-08-01: Oncology Clinicians’ Knowledge, Attitudes and Practices Regarding Fertility Preservation (2010) (1)
5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib (2009) (1)
Abstract P6-11-10: IBL2001: Phase I/II study of a novel dose-dense schedule of oral indibulin for the treatment of metastastic breast cancer. (2012) (1)
A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer. (2022) (1)
Nuclear Pore Complex (2011) (1)
Implications of growth kinetic concepts for cancer chemoprevention. (1988) (1)
Abstract OT3-1-01: A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy (2012) (1)
Refining the origins of breast cancer (1995) (1)
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations (2014) (1)
Abstract 3908: Norton-Simon modeling for the optimization of dose and schedule of palifosfamide in breast cancer (2012) (1)
Non-monotonic dose-response to chemotherapy of murine b-16 melanoma (mm). Abstr. (1981) (1)
Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (1)
Dichloroplatinum in malignant mesothelioma. (1984) (1)
Abstract P6-20-03: Tumor epichaperome expression using124I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC) (2019) (1)
Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC). (2014) (1)
Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast (2017) (1)
Role of Modeling in Pharmacotherapeutics (2006) (1)
Abstract P2-16-11: Impact of adjuvant trastuzumab (T) with chemotherapy on breast cancer specific and cardiac outcomes in older women with small, node-negative HER2-positive breast cancer (2013) (1)
Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer with central nervous system metastases. (2018) (1)
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer (2021) (1)
An ecosystem services approach to productive land management in a farm-scale catchment. (2013) (0)
BRCA haploinsufficiency in human breast tumorigenesis (2005) (0)
Larry Norton--president-elect of ASCO. American Society of Clinical Oncology. Interviewed by Ezzie Hutchinson. (2000) (0)
Colorectal Cancer: Current Concepts in Diagnosis and Treatment (1987) (0)
Determination of cancer susceptibility in probands with breast and ovarian cancer (2014) (0)
Implications of a fractal model of neoplasia for the detection of microscopic breast cancer (1996) (0)
Abstract P2-01-02: Whole exome sequencing analysis of the progression from ductal carcinomain situto invasive ductal carcinoma (2019) (0)
Abstract PD8-09: Bi-allelic alterations in homologous recombination (HR) DNA repair-related genes as the basis for HR defects in human cancers: A pan-cancer genomics and functional analysis (2018) (0)
The sialyl-glycolipid SSEA 4 marks a subpopulation of chemotherapy resistant breast cancer cells with mesenchymal features (2015) (0)
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy (2022) (0)
Abstract P4-02-18: Impact of clonal hematopoiesis on disease progression following CDK4/6 inhibitor therapy (2023) (0)
Evaluating the association between clonal hematopoiesis and germline pathogenic and likely pathogenic variants in cancer predisposition genes. (2020) (0)
Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer. (2017) (0)
Abstract 961: TCF7 promotes a mammary cancer-stem-like phenotype leading to metastasis via potentiation of a hybrid epithelial/mesenchymal (E/M) phenotype (2022) (0)
314 Adjuvant endocrine and chemotherapy for early breast cancer (1997) (0)
Drug Resistance In The Treatment of Cancer: Effect of dose and schedule on chemotherapeutic drug resistance (1998) (0)
Abstract 6591: A universal atlas of cellular and oncogenic phenotypes (2023) (0)
Global Oncology Medical Diplomacy Working Group Inaugural Meeting: Defining Worldwide Barriers to Germline Genomics in Cancer Prevention and Management (2023) (0)
Abstract 4975: A small molecule pan Id protein antagonist shows strong antitumor activity (2017) (0)
Abstract PD1-4: Somatic leukemogenic mutations associated with infiltrating white blood cells in breast cancer patients (2015) (0)
Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer (2022) (0)
Wasserstein Image Local Analysis: Histogram of Orientations, Smoothing and Edge Detection (2022) (0)
Abstract 968: Loss of glutathione peroxidase 2 promotes epithelial to mesenchymal transition and breast cancer metastasis (2022) (0)
Abstract P2-05-08: Mucinous breast carcinomas: A genomically distinct subtype of estrogen receptor-positive invasive breast cancers (2018) (0)
Abstract P5-20-07: Phase II Trial of Dasatinib in Combination With Weekly Paclitaxel for Patients with Metastatic Breast Carcinoma (2012) (0)
SU-E-J-115: Using Markov Chain Modeling to Elucidate Patterns in Breast Cancer Metastasis Over Time and Space. (2014) (0)
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases (2022) (0)
Abstract 4426: Redox regulation of tumor cell heterogeneity in the PyMT mammary tumor model revealed by single cell RNA sequencing (2020) (0)
Abstract 6541: Geometry of gene expression network reveals potential novel indicator in Ewing sarcoma (2023) (0)
Gene-expression profiling to demonstrate select neutrophils from breast cancer patients versus healthy women as cytotoxic against breast cancer cells via novel chemokine-mediated mechanisms. (2014) (0)
Phase Ib/II open-label study of Ad-RTS-hIL-12 + veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients (2016) (0)
Innovative approaches to the treatmnet of advanced breast cancer (1997) (0)
Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program (2022) (0)
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes (2017) (0)
OP-JNCI190159 107..110 (2020) (0)
Neoadjuvant weekly paclitaxel followed by FAC (2005) (0)
EGF Receptor Mabs and Chemotherapy in Breast Cancer. (1996) (0)
Rapid delivery of multiple courses of high-dose chemotherapy (HDC) using G-CSF & Peripheral blood progenitors (PBP) in patients (PTS) with metastatic breast cancer (MBC) (1993) (0)
A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer. (2014) (0)
Abstract GS3-03: Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities (2022) (0)
Controlled and Uncontrolled Stochastic Norton-Simon-Massagué Tumor Growth Models (2019) (0)
Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
Innovative approaches to the treatment of advanced breast cancer: introduction. (1997) (0)
Abstract OT2-17-02: The ARETHA Study: A phase 2 randomized control trial of Eribulin with Evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer and metabolic dysfunction (2023) (0)
Abstract P5-02-01: Regulated intratumoral expression of IL-12 in combination with cytotoxic agents as a strategy for the treatment of metastatic breast cancer (2013) (0)
Abstract P4-08-01: Effectiveness of electroacupuncture versus auricular acupuncture in breast cancer survivors with chronic musculoskeletal pain: The PEACE randomized clinical trial (2022) (0)
More frequent dosing can prevent cancer cell regrowth (2011) (0)
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (0)
The novel cytotoxicity of neutrophils in the peripheral blood of breast cancer patients versus women without breast cancer. (2011) (0)
Abstract 1993: Gluthathione peroxidase 2 downregulation in the PyMT mammary tumor model leads to an aggressive phenotype due to stimulation of angiogenesis and tumor stemness via HIF1 alpha signaling (2019) (0)
Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity. (2009) (0)
Abstract P2-10-01: The genomic landscape of breast cancer in African American women (2020) (0)
Association of in Lymph Node Metastases With Outcome of Breast Cancer (0)
Redox signaling regulates breast cancer metastasis via HIF1α-stimulated EMT dynamics and metabolic reprogramming (2022) (0)
Reply to “Multicentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomas” (2018) (0)
P4-16-06: Expression Patterns of Receptor Activator of Nuclear Factor-kB (RANK) and Src in a Series of Primary Breast Tumors (BT) and Bone Metastases (BM) in Patients (pts) with Metastatic Breast Cancer (MBC). (2011) (0)
Abstract P6-10-05: A pilot study of radiation (RT) and CTLA4-mediated checkpoint blockade with tremelimumab for the treatment of breast cancer brain metastases (BCBM) (2017) (0)
Efficacy of a mitochondrial toxin, F16, in a multi-ATP-depleting regimen + chemotherapy on human breast cancer (MDA-MB-468) xenografts. (2004) (0)
Abstract 1928: Prediction of neoadjuvant treatment outcomes with multimodal data integration in breast cancer (2022) (0)
Chemoprevention Breast Cancer Workshop, November 20, 1987 Panel Discussions (1988) (0)
Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors (2021) (0)
Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
Geometric Network Analysis Defines Poor-Prognosis Subtypes in Multiple Myeloma (2022) (0)
Inflammatory breast cancer (IBC) treated with combined modality therapy (1991) (0)
Title: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early- stage breast cancer with comprehensive immune profiling. Authors and affiliations: (2016) (0)
Abstract P2-16-10: Disease free survival rate with dose dense Doxorubicin and Cyclophosphamide followed by weekly Paclitaxel with Trastuzumab and Pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience (2020) (0)
TERT Hotspot Promoter Mutations and TERT Gene Amplification in Phyllodes Tumors of the Breast (2016) (0)
Abstract OT2-01-03: A phase 1/2 study of once-daily oral VT-464 in patients with advanced androgen receptor (AR) positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC) (2016) (0)
Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet ! (2003) (0)
Abstract P1-05-04: Intra-tumor genetic heterogeneity and histologic heterogeneity within metaplastic breast cancers: Genotypic-phenotypic correlations (2017) (0)
Simultaneous Group Discussions with Invited Speakers (2005) (0)
Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). (2011) (0)
Incidence of ovarian cancer in BRCA-negative hereditary breast cancer families. (2004) (0)
Abstract 2061: Protein network analysis uncovers a poor-survival subtype in multiple myeloma (2023) (0)
Attitudes and Concerns of Pre-Pubescent and Pubescent Girls about Breast Health and Breast Cancer: An Unmet Need. (2009) (0)
Weekly T rastuzumab a nd P aclitaxel T herapy f or M etastatic Breast C ancer W ith A nalysis o f E fficacy b y HER2 Immunophenotype a nd G ene A mplification (2001) (0)
High Resolution Comparative Genomic Hybridization (CGH) Indicates That Genomic Profiles Are Very Heterogeneous for HER2 and TOP2A in FISH-Amplified Human Breast Cancer Specimens. (2009) (0)
Abstract P5-01-07: Select neutrophils inhibit breast cancer metastases in patients via chemokine-mediated mechanisms (2013) (0)
The novel cytotoxicity of neutrophils in the peripheral blood of patients with breast cancer versus healthy women. (2011) (0)
P1-01-03: The Cytotoxicity of Select Neutrophils in Cancer Patients and the Role of Chemokines in Inducing Neutrophil Cytotoxicity. (2011) (0)
Identification of a new breast cacner risk locus in a genome-wide association study of Ashkenazi Jews (2008) (0)
Abstract P4-05-11: Methylation profiling of mucinous breast cancer (2020) (0)
Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients (2020) (0)
Abstract 1415: Anti-metastatic properties of tumor-entrained neutrophils (2012) (0)
Abstract PR04: Integrin-mediated mechano-transduction controls HER2 oncogenic signaling and activation of YAP in breast cancer (2020) (0)
Antibody and CD 8 + TCell Responses against HER 2 / neu Required for Tumor Eradication after DNA Immunizationwith a Flt-3 Ligand FusionVaccine (2007) (0)
Contents, Vol. 51, Supplement 1, 1994 (1994) (0)
Abstract 5703: Oncologic therapy shapes the fitness landscape of clonal hematopoiesis (2020) (0)
In Memoriam: José Baselga's Journey in Cancer Medicine (2021) (0)
Impact of clonal hematopoiesis on tumor control following radiation therapy. (2022) (0)
Re: "We may be lost, but we're sure makin' good time". (1994) (0)
MS1-2: Tumor Entrained Neutrophils Inhibit Seeding in the Pre-Metastatic Lung. (2011) (0)
A prospective evaluation of the relationship between bone mineral density and breast cancer. (2014) (0)
Faculty Opinions recommendation of Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. (2014) (0)
Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients (2020) (0)
Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up (2018) (0)
Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer (2003) (0)
Topo2a and Her2 Co-Amplification Is Uncommon by High Resolution Representational Oligonucleotide Microarray Analysis (Roma) in Human Breast Cancer (2009) (0)
Dose-Response T rial o f M egestrol A cetate i n A dvanced Breast C ancer: C ancer a nd L eukemia G roup B Phase I II S tudy 8 741 (1999) (0)
Erratum to: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma (2009) (0)
Interventional immunotherapy in breast cancer (2012) (0)
Use of genome-wide scan in women with breast cancer to identify common germline variants that may be associated with recurrence. (2009) (0)
Abstract OT1-01-05: Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer (2016) (0)
Abstract IA28: Integrin-mediated mechano-transduction controls HER2 oncogenic signaling and activation of YAP in breast cancer (2020) (0)
Abstract P4-02-01: Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer (2023) (0)
Abstract P4-13-20: Activity of HP-based therapies as third and later lines for the treatment of HER2-positive metastatic breast cancer: A retrospective study from a single institution (2016) (0)
INTEGRATION OF NEW THERAPIES INTO THE MANAGEMENT OF BREAST CANCER (1998) (0)
Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy. (2017) (0)
Male breast cancer : genomic profiling 1 The Genomic Landscape of Male Breast Cancers (2016) (0)
Objective and subjective vulvovaginal symptoms in breast cancer patients. (2020) (0)
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (0)
Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival (2023) (0)
Reply to S. Mahesh (2012) (0)
Anti-tumor effects of an ID antagonist with no observed acquired resistance (2021) (0)
Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-Positive metastatic breast cancer (MBC) after prior HP- or TDM/P-based therapy. (2016) (0)
Evolving concepts in the adjuvant systemic therapy of operable breast cancer. (1992) (0)
Abstract P1-14-17: Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience (2016) (0)
Abstract B40: Paracrine interactions through CXCL1/2 chemokines promote breast cancer metastasis and chemoresistance (2012) (0)
APhase II Trial of Erlotinib in Combinationwith Bevacizumab in Patients withMetastatic Breast Cancer (2008) (0)
Dealing with the tyranny of certainty in the (medical) digital age (2017) (0)
Introduction to the Session: Combinations of Molecularly Targeted Agents in Cancer (2014) (0)
Faculty Opinions recommendation of Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. (2014) (0)
Abstract OT1-19-01: A Single Arm Phase 2 Study of Peri-Operative Checkpoint-Mediated Immune Therapy and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer (2023) (0)
Identifying somatic oncogenic mutations in leukocytes that infiltrate primary breast cancers. (2015) (0)
Abstract 3282: Determination of cancer susceptibility in probands with breast and ovarian cancer (2014) (0)
Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer (2005) (0)
Abstract P2-05-03: Novel driver genetic alterations in MYB-NFIB-negative breast adenoid cystic carcinomas (2018) (0)
IS THE MAXIMUM TOLERATED DOSE (MDT) STILL THE OPTIMAL GOAL FOR CANCER DRUGS? (2021) (0)
FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer (2015) (0)
TOWARD THE DEVELOPMENT OF MOLECULAR ONCOLOGY: THE INTEGRATION OF MOLECULAR EPIDEMIOLOGY AND ENVIRONMENTAL ONCOLOGY (2004) (0)
1065 Clinical observations of axillary involvement for tubular, lobular and ductal carcinomas of the breast (1996) (0)
Association of personal and family history with decision to undergo risk-reducing salpingo-oophorectomy in BRCA mutation carriers (2005) (0)
A new method for sreening anti-cancer agents on solid tumors. Abstr. (1978) (0)
Stochastic Norton–Simon–Massagué Tumor Growth Modeling: Controlled and Mixed-Effect Uncontrolled Analysis (2021) (0)
Management of advanced breast cancer: patient needs, challenges and new treatment options. Introduction. (1996) (0)
Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2+) breast cancer. (2015) (0)
Society for Integrative Oncology First International Conference, New York City, November 2004. Keynote address. (2005) (0)
Abstract 3889: Genetic heterogeneity and distinct driver mutations in synchronous primary and metastatic breast cancers from therapy-naïve patients (2015) (0)
Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations (2016) (0)
Mobile mammography in New York City: analysis of 32,350 women utilizing a screening mammogram program (2022) (0)
igration of Transfused Granulocytes in Leukopenic Dogs (2005) (0)
Cancer as a Disease of Self-Seeding (2011) (0)
Abstract P6-18-30: Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC) (2019) (0)
O PREDICTION OF AXILLARY STATUS FROM SENTINEL LYMPH NODE TESTING WITH AN INTRAOPERATIVE RT-PCR TEST – MULTI-CENTER ANALYSIS OF 1138 PATIENTS (2009) (0)
Abstract P6-11-12: A Novel Capecitabine Schedule (7 on — 7 off) Is Feasible with Lapatinib for Patients with HER2-Positive Metastatic Breast Cancer Refractory to Trastuzumab (2010) (0)
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study (2022) (0)
Cancer heterogeneity is defined by normal cellular trade-offs (2023) (0)
Comparative efficacy of bone marrow engraftment following high-dose carboplatin plus cyclophosphamide versus high-dose CBDCA/TAXOL , when rescued with Txl/cyclophosphamide and GCSF mobilized peripheral blood progenitor cells (1994) (0)
Abstract P2-13-06: Clinical implication of HER2 status change after neoadjuvant chemotherapy with Trastuzumab and Pertuzumab (HP) in patients with HER2-positive breast cancer (2022) (0)
Abstract P2-03-08: Mutational landscape of metaplastic breast carcinomas (2015) (0)
Rethinking agricultural systems in the UK, Oxford, UK, 18-19 December 2013. (2013) (0)
Abstract P3-07-02: Metaplastic breast carcinomas and uterine carcinosarcomas are histologically and genetically related (2019) (0)
Experimental and Clinical Activity of Mitomycin C and c / s-Diamminedichloroplatinum in Malignant Mesothelioma 1 (2006) (0)
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer (2018) (0)
Abstract P2-01-02: Capturing intra-tumor genetic heterogeneity in cell-free plasma DNA from patients with oligometastatic breast cancer (2016) (0)
Faculty Opinions recommendation of Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. (2014) (0)
Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer. (2016) (0)
Abstract OT1-01-04: A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy (2020) (0)
Institutional Knowledge at Singapore Management Factors Influencing Treatment Patterns in Breast Cancer Patients Age 75 and Over (2019) (0)
IBL2001: Phase (ph) I/II study of a novel dose-dense (dd) schedule of indibulin for the treatment of metastastic breast cancer. (2012) (0)
The cytotoxicity of select neutrophils in breast cancer patients and the role of chemokines in neutrophil cytotoxicity. (2013) (0)
Abstract P4-21-34: Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy (2017) (0)
OP-ANNO180192 1634..1657 (2018) (0)
Abstract P1-05-03: The genomic landscape of breast metaplastic carcinoma (2017) (0)
Efficacy of a mitochondrial toxin, F16, in a multi-ATP-depleting regimen + chemotherapy on human breast cancer (MDA-MB-468) xenografts (2004) (0)
Abstract P1-09-14: Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up (2017) (0)
Modeling the Development of MÃ©tastasesfrom Primary and Locally Recurrent l\imors: Comparison with a Clinical Data Base for Prostatic Cancer1 (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Larry Norton?

Larry Norton is affiliated with the following schools:

Larry Norton's Academic­Influence.com Rankings

Larry Norton's Degrees

Similar Degrees You Can Earn

Why Is Larry Norton Influential?

Larry Norton's Published Works

Published Works

What Schools Are Affiliated With Larry Norton?

Larry Norton's AcademicInfluence.com Rankings